Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020

$3,495.00

The Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2020
Number of pages
300+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP22012

The Global Cancer Monoclonal Antibody Partnering 2014-2020 report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in cancer monoclonal antibody partnering deals
  • Most active companies in cancer monoclonal antibody partnering
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer monoclonal antibody partnering contract documents
  • Top cancer monoclonal antibody deals by value

 

This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

 

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

 

  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human aAb

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

 

Key benefits

 

Global Cancer Monoclonal Antibody Partnering Terms & Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of cancer monoclonal antibody deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
  • Comprehensive access to over 450 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
  • Identify most active companies in cancer monoclonal antibody partnering
  • Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Spot the emerging companies in the cancer monoclonal antibody area

 

Report scope

 

Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

 

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:

 

  • Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2014
  • Analysis of cancer monoclonal antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 450 cancer monoclonal antibody deal records
  • The leading cancer monoclonal antibody deals by value since 2014

 

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • Monoclonal antibody type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 450 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Cancer Monoclonal Antibody Partnering 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of cancer monoclonal antibody deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
  • Comprehensive access to over 450 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
  • Identify the most active companies engaged in cancer monoclonal antibody partnering
  • Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Cancer monoclonal antibody dealmaking

 

2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Most active Cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody partnering by deal type
2.5. Cancer monoclonal antibody partnering by therapy area
2.6. Deal terms for Cancer monoclonal antibody partnering
2.6.1 Cancer monoclonal antibody partnering headline values
2.6.2 Cancer monoclonal antibody deal upfront payments
2.6.3 Cancer monoclonal antibody deal milestone payments
2.6.4 Cancer monoclonal antibody royalty rates

 

Chapter 3 – Leading Cancer monoclonal antibody deals

 

3.1. Introduction
3.2. Top Cancer monoclonal antibody deals by value

 

Chapter 4 – Most active Cancer monoclonal antibody dealmakers

 

4.1. Introduction
4.2. Most active Cancer monoclonal antibody dealmakers
4.3. Most active Cancer monoclonal antibody partnering company profiles

 

Chapter 5 – Cancer monoclonal antibody contracts dealmaking directory

 

5.1. Introduction
5.2. Cancer monoclonal antibody contracts dealmaking directory

 

Chapter 6 – Cancer monoclonal antibody dealmaking by technology type

 

Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Cancer monoclonal antibody deals by company A-Z

 

Appendix 2 – Cancer monoclonal antibody deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Cancer monoclonal antibody deals by deal type

 

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

 

Appendix 4 – Cancer monoclonal antibody deals by therapy area

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures

 

Figure 1: Therapeutic antibody definitions
Figure 2: Cancer monoclonal antibody partnering since 2014
Figure 3: Active Cancer monoclonal antibody dealmaking activity since 2014
Figure 4: Cancer monoclonal antibody partnering by deal type since 2014
Figure 5: Cancer monoclonal antibody partnering by disease type since 2014
Figure 6: Cancer monoclonal antibody deals with a headline value
Figure 7: Cancer monoclonal antibody deals with an upfront value
Figure 8: Cancer monoclonal antibody deals with a milestone value
Figure 9: Cancer monoclonal antibody deals with a royalty rate value
Figure 10: Top Cancer monoclonal antibody deals by value since 2014
Figure 11: Most active Cancer monoclonal antibody dealmakers since 2014
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3D Medicines, 3SBio, 4D Pharma, Abbvie, AbClon, Abpro, Abzena, Accord Healthcare, Acerta Pharma, Actinium Pharmaceuticals, Adaptimmune, Adaptive Biotechnologies, Adlai Nortye, Aduro BioTech, Advaxis, Aeglea BioTherapeutics, AffaMed Therapeutics, Affimed Therapeutics, Affinita Biotech, AGC Biologics, Agenus Bio, Alligator Bioscience, Alphamab Biopharmaceuticals, Alvogen, Ambrx, Amgen, Amneal Pharmaceuticals, AnaptysBio, Anthera Pharmaceuticals, Antigen Express, Apceth, Apeiron Biologics, Aperion Biologics, Apexigen, Arcus Biosciences, arGEN-X, argenx, Array Biopharma, Ascenion, Ascentage Pharma, Aslan Pharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Athenex, Atlab Pharma, AVEO Oncology, Aytu BioScience, Basilea Pharmaceutica, Bavarian Nordic, Baxalta, Bayer, BeiGene, BerGenBio, Biametrics, Bio-Thera Solutions, BioAtla, Bioceros, BiocerOX Products, Biodesix, Bio Farma, BioInvent, BiolineRX, BioMarker Strategies, Biomunex Pharmaceuticals, Bioncotech Therapeutics, BioNTech, Biothera, BioXcel, BliNK Biomedical, BliNK Therapeutics, Boehringer Ingelheim, Bpifrance, Bristol-Myers Squibb, C-Bridge Capital, California Institute for Regenerative Medicine, Calithera Biosciences, Cancer Prevention and Research Institute of Texas, Cancer Research Technology, Cancer Research UK, CanCure, Candel Therapeutics, Cantargia, CBT Pharmaceuticals, CDI Laboratories, Celgene, Celldex Therapeutics, Cell Signaling Technology, Celltrion, Centre for Drug Research and Development (CDRD), Checkmate Pharmaceuticals, Chi-Med, Chiome Bioscience, Cilag AG, Cipla, City of Hope Comprehensive Cancer Center, Clal Biotech, Clinica Universidad Navarra, Clovis Oncology, CMAB Biopharma, CMC Biologics, Coherus Biosciences, Cold Genesys, Columbia University, Compugen, Conkwest, Corvus Pharmaceuticals, Covalab, Crescendo Biologics, Crown Bioscience, CStone Pharmaceuticals, Cullinan Oncology, CureTech, Curie-Cancer, CytomX Therapeutics, Cytovance Biologics, Daiichi Sankyo, Dako, Debiopharm, Diaprost, Distributed Bio, DNAtrix, Dynavax Technologies, eFFECTOR Therapeutics, Eisai, Eleven Biotherapeutics, Eli Lilly, ElsaLys Biotech, EMD Millipore, EMD Serono, Enumeral Biomedical, Enzo Biochem, EpiThany, Essex Bio-Technology, Eureka Therapeutic, Eurofarma, European Union Regional Development Fund, EUSA Pharma, Eutilex, Everest Medicines, Exelixis, Faron Pharmaceuticals, Fate Therapeutics, Five Prime Therapeutics, FLX Bio, Forty Seven, Fosun Kite Biotechnology, Fred Hutchinson Cancer Research Center, Fuhong Hanlin, Galaxy Biotech, Gallus Biopharmaceuticals, GamaMabs Pharma, Genentech, Genexine, Gen Ilac, Genmab, Genome and Company, Genor Biopharma, GenScript USA, Georgetown University, GlaxoSmithKline, Glenmark Pharmaceuticals, Glycotope Biotechnology, Glythera, Goodwin Biotechnology, Gossamer Bio, Gradalis, Gritstone Oncology, H-Immune, H3 Biomedicine, Halozyme Therapeutics, Harbour Biomed, Heidelberg Pharma, Henlius Biotech, Hikma Pharmaceuticals, Hoffmann La Roche, Hospira, Humanigen, Hummingbird Bioscience, Hutchison MediPharma, I-mab, i2 Pharmaceuticals, IBA Molecular Imaging, iDD Biotech, Idera Pharmaceuticals, Illumina, ImaginAb, ImCheck Therapeutics, ImClone Systems, Immatics Biotechnologies, Immune Design, Immune Pharmaceuticals, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunomedics, Immunovaccine, Immutep, IMPACT Therapeutics, Incyte, Infinity Pharmaceuticals, Innate Pharma, Innovent Biologics, Inserm, Inserm Transfert, Institute of Biophysics, Intensity Therapeutics, Invenra, InxMed, IO Biotech, IONTAS, Ipca Laboratories, IRBM, ISA Pharmaceuticals, IsoTherapeutics, iTeos Therapeutics, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jazz Pharmaceuticals, JHL Biotech, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson Innovation, Jounce Therapeutics, Juno Therapeutics, Junshi Biosciences, KAHR Medical, Kalbe Genexine Biologics, Kelun-Biotech Biopharmaceutical, Kiniksa Pharmaceuticals, Kintor, Kite Pharma, Kolltan Pharmaceuticals, Kymab, Kyowa Hakko Kirin, Leads Biolabs, Leap Therapeutics, Lee's Pharmaceutical, Leica Biosystems, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, Lonza, Lumos Pharma, Lupagen, MAB Discovery, Mabion, MabVax Therapeutics, mAbXience, Macquarie University, Macrogenics, Mapp Biopharmaceutical, Massachusetts General Hospital, Mayo Clinic, MD Anderson Cancer Center, MedImmune, Medison Pharma, Medivation, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merrimack Pharmaceuticals, Mersana Therapeutics, MicroConstants, Minomic, Mitra Biotech, Mitsubishi Tanabe Pharma, Moleculin Biotech, MorphoSys, Morphotek, Mount Sinai Health System, MSD, Mundipharma, Mustang Bio, Mylan Laboratories, Mylan Pharmaceuticals, Myriad Genetics, NantBioScience, NantCell, NantKwest, NantWorks, Nascent Biotech, National Cancer Institute, National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Institutes of Health, NCIC Clinical Trials Group, Nektar Therapeutics, NeoBiotechnologies, NeoImmuneTech, Neon Therapeutics, NeuClone, Neuroblastoma and Medulloblastoma Translational Research, Nexvet, Northern Biologics, Novartis, Novelogics Biotechnology, NovImmune, Novo Nordisk, Noxxon Pharma, Numab, Oncobiologics, OncoCare Therapeutics, OncoImmune, Oncologie, Oncolytics Biotech, OncoMed Pharmaceuticals, OncoQuest, OncoSec Medical, Oncosynergy, Oncothyreon, Oncternal Therapeutics, Oncurious, Ono Pharmaceutical, Open Monoclonal Technology, OSE Immunotherapeutics, Oxford BioTherapeutics, Panacea Pharmaceuticals, Pascal Biosciences, Patheon, PDS Biotechnology, Pelican Therapeutics, Peregrine Pharmaceuticals, Personal Genome Diagnostics, Personalis, Pfizer, Phanes Therapeutics, PharmAbcine, Pharmacyclics, Pharmapark, Pierre Fabre, Pneuma Respiratory, Poseida Therapeutics, Precision Biologics, Prestige BioPharma, ProBioGen, Progenics Pharmaceuticals, ProtoKinetix, PULSALYS, Quantum Leap Health Care Collaborative, Queensland Institute of Medical Research (QIMR), Quest PharmaTech, Regeneron Pharmaceuticals, Rexahn Pharmaceuticals, Roche, Rockefeller University, Roswell Park Cancer Institute, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, Sanofi, Sanofi-Aventis, Sarah Cannon Research Institute, SATT Sud-Est, Schrodinger, Sea Lane Biotechnologies, Seattle Genetics, Selecxine, Selexis, SELLAS Life Sciences Group, Sensei Biotherapeutics, Serum Institute of India, Seven and Eight Biopharmaceuticals, Shenogen Pharma, Shenzhen Chipscreen Biosciences, Shire Pharmaceuticals, Simcere Pharmaceuticals, Sirnaomics, Sorrento Therapeutics, Sosei Heptares, Specialized Medical Services-oncology, Spring Bank Pharmaceuticals, Strata Oncology, Sud Investments, Surface Oncology, Swedish Orphan Biovitrum, Symphogen, Syndax Pharmaceuticals, Synlogic, Syros Pharmaceuticals, Taiho, Takeda Pharmaceutical, TARIS Biomedical, Telix Pharmaceuticals, TeneoBio, Tesaro, Tessa Therapeutics, Tetragenetics, TetraLogic Pharmaceuticals, TG Therapeutics, Theradiag, Theranyx, ThromboGenics, Tikcro Technologies, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, Torque Therapeutics, TPG Capital, TRACON Pharmaceuticals, Transgene, TransPerfect Life Sciences, Trianni, Trieza Therapeutics, Turgut Ilaclari, UCB, UMass Memorial Medical Center, Universite Claude Bernard Lyon, University of Bergen, University of British Columbia, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Cologne, University of Illinois at Chicago, University of Massachusetts Medical School, University of Minnesota, University of New Mexico, University of Nottingham, University of Wisconsin Carbone Cancer Center (UWCCC), Unum Therapeutics, UroGen Pharma, Vaccinex, Valneva, Vaximm, Vcell Healthcare, Vedanta Biosciences, Ventana Medical Systems, Verastem, Verseau Therapeutics, VIB, Viela Bio, Viralytics, Vyriad, Wilex, WindMIL Therapeutics, XBiotech, Xoma, Yale University, Yeda Research and Development Company, ZAI Laboratory, Zenoaq, Zenyaku Kogyo, Zhejiang Bossan Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zydus Cadila

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.